Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Xilio Therapeutics reported a quarterly loss of $0.03 per share, which aligns with the Zacks Consensus Estimate, showing improvement from a loss of $0.22 per share a year ago [1] - The company posted revenues of $19.07 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 28.51%, compared to revenues of $2.26 million in the same quarter last year [2] - Xilio Therapeutics shares have declined approximately 19% year-to-date, contrasting with a 16.5% gain in the S&P 500 [3] Financial Performance - The company has not surpassed consensus revenue estimates over the last four quarters [2] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $7.96 million, and for the current fiscal year, it is -$0.45 on revenues of $45.65 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Xilio Therapeutics is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 35% of Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8] - Another company in the same industry, Immatics, is expected to report a quarterly loss of $0.50 per share, with revenues projected to decline by 77.9% year-over-year [9]